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Objectives: Vascular endothelial growth factor (VEGF), a potent angiogenic
mediator, can be delivered to targeted tissues by means of a replication-
deficient adenovirus (Ad) vector. We hypothesized that direct administra-
tion of Ad vector expressing the VEGF121 complementary deoxyribonucleic
acid (AdGVVEGF121.10) into regions of ischemic myocardium would en-
hance collateral vessel formation and improve regional perfusion and
function. Methods: Yorkshire swine underwent thoracotomy and placement
of an Ameroid constrictor (Research Instruments & MFG, Corvallis, Ore.)
on the circumflex coronary artery. Three weeks later, myocardial perfusion
and function were assessed by single photon emission computed tomogra-
phy imaging (SPECT) with 99mTc-labeled sestamibi and by echocardiogra-
phy during rest and stress. AdGVVEGF121.10 (n 5 7) or the control vector,
AdNull (n 5 8), was administered directly into the myocardium at 10 sites
in the circumflex distribution (108 pfu/site). Four weeks later, these studies
were repeated and ex vivo angiography was performed. Results: SPECT
imaging 4 weeks after vector administration demonstrated significant
reduction in the ischemic area at stress in AdGVVEFG121.10-treated
animals compared with AdNull control animals (p 5 0.005). Stress
echocardiography at the same time demonstrated improved segmental wall
thickening in AdGVVEGF121.10 animals compared with AdNull control
animals (p 5 0.03), with AdGVVEGF121.10 animals showing nearly nor-
malized function in the circumflex distribution. Collateral vessel develop-
ment assessed by angiography was also significantly greater in AdGV-
VEGF121.10 animals than in AdNull control animals (p 5 0.04), with
almost complete reconstitution of circumflex filling in AdGVVEGF121.10
animals. Conclusions: An Ad vector expressing the VEGF121 cDNA induces
collateral vessel development in ischemic myocardium and results in
significant improvement in both myocardial perfusion and function. Such a
strategy may be useful in patients with ischemic heart disease in whom
complete revascularization is not possible. (J Thorac Cardiovasc Surg
1998;115:168-77)
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Despite continued advances in the treatment ofischemic heart disease, a large population of
individuals with diffuse coronary artery disease ex-
ists for whom conventional therapies such as percu-
taneous angioplasty and bypass surgery provide little
or no benefit. A new strategy that may be applicable
to such patients is “therapeutic angiogenesis,” the
induction of new blood vessel development into
areas with limited blood flow.1, 2 Therapeutic angio-
genesis capitalizes on the discovery of protein me-
diators that elicit angiogenesis, a complex process
that includes the migration and proliferation of
endothelial cells, vascular tube formation, and link-
age to the preexisting vascular network.3, 4 Several
of these protein mediators have been shown to
promote revascularization of ischemic tissues in
models of myocardial or peripheral ischemia.1-3, 5-9
Vascular endothelial growth factor (VEGF), a
homodimeric 34 to 46 kDa heparin-binding glyco-
protein, is the most specific of the known angiogenic
mediators because of localization of its receptors
almost exclusively on endothelial cells.10-12 The hu-
man VEGF gene is expressed as four isoforms
secondary to posttranscriptional splicing, producing
proteins of 121, 165, 189, and 206 residues. The
observations that VEGF and VEGF receptors (flk-
1/KDR and flt-1) are up-regulated under ischemic
conditions is consistent with the concept that VEGF
is an endogenous mediator of angiogenesis.11-13
Gene therapy, in which the complementary de-
oxyribonucleic acid (cDNA) for VEGF is delivered
directly to tissues, has the potential to induce local-
ized VEGF expression that is of limited duration,
thus avoiding the toxicity and promiscuous angio-
genesis potentially associated with systemic protein
therapy.14-18 In examining this hypothesis, the
present study uses a porcine myocardial ischemia
model to demonstrate that direct administration of a
replication-deficient adenovirus (Ad) vector coding
for the human VEGF121 cDNA (AdGV-
VEGF121.10) into ischemic myocardium induces a
“biologic bypass”—collateralization around a site of
coronary occlusion, with concomitant improvement
in regional myocardial perfusion and function dur-
ing stress-induced myocardial ischemia.
Methods
Experimental model of myocardial ischemia. A model
of chronic myocardial ischemia was created in Yorkshire
swine (28 to 30 kg). All animal care procedures were in
accordance with institutional guidelines. Animals were
sedated with intramuscular tiletamine and zolazepam
(Telazol, 3.3 mg/kg) and xylazine (0.10 mg/kg), intubated,
and sedation was maintained with 0.5% to 2.0% isoflu-
rane. A limited left thoracotomy was performed in a
sterile fashion through the fifth intercostal space and a
small incision was made in the pericardium. A 2.5 mm
internal diameter Ameroid constrictor (Research Instru-
ments & MFG, Corvallis, Ore.) was placed around the
circumflex artery as proximally as possible. Topical lido-
caine 1% solution was applied to the circumflex artery at
the Ameroid constrictor site to prevent coronary artery
spasm. The pericardium and chest were then closed and
the animal was allowed to recover.
Ad vectors. The replication-deficient vector AdGV-
VEGF121.10 is an E1a–, partial E1b–, partial E3–Ad
vector that contains an expression cassette in the E1
position (right to left) containing the cytomegalovirus
immediate early promoter/enhancer, an artificial splice
sequence, the human VEGF121 cDNA, and the SV40
polyA/stop signal. AdNull (similar to AdGVVEGF121.10,
but with no gene in the expression cassette) was used as a
control vector.19 All Ad vectors were propagated and
titrated in 293 cells, purified by cesium chloride density
purification, dialyzed, and stored at –70° C.20 The viral
stocks were demonstrated to be free of replication-com-
petent wild type Ad. Biologic activity of the VEGF121
transgene product was confirmed by demonstrating pro-
liferation of human umbilical vein endothelial cells using
[3H]thymidine incorporation, and in vivo confirmation of
transgene expression was determined by enzyme-linked
immunosorbent assay analysis of myocardial biopsy spec-
imens obtained from AdVEGF121.10 injection sites 3
days after vector administration.17
In vivo administration of Ad vectors. Three weeks after
Ameroid constrictor placement, the left thoracotomy was
reopened and administration of the therapeutic vector,
AdGVVEGF121.10, or the control vector, AdNull, was
performed by direct myocardial injection (Fig. 1). Each
vector was injected at 10 sites, each in 100 ml phosphate-
buffered saline solution, pH 7.4, in the circumflex distri-
bution (108 pfu/injection). Pacing wires were placed in the
left atrial appendage and tunneled subcutaneously for
subsequent stress technetium 99m (99mTc)-labeled sesta-
mibi (Cardiolite, DuPont Pharma, N. Billerica, Mass.)
assessment of regional myocardial perfusion by single
photon emission computed tomography (SPECT) and
echocardiographic assessment of regional wall thickening.
99mTc-labeled sestamibi assessment of regional myo-
cardial perfusion. Regional myocardial perfusion was
evaluated during rest and stress 3 weeks and 7 weeks after
placement of the Ameroid constrictor by means 99mTc-
sestamibi SPECT. During rapid atrial pacing at 200
beats/min, animals received intravenous injections of a 5
mCi bolus of 99mTc-sestamibi and pacing was continued
for approximately 3 minutes. The animals were then
placed in the prone position in an ADAC Vertex dual
detector gamma camera system (ADAC Laboratories,
Milpitas, Calif.). A nongated SPECT study was then
acquired in a “step-and-shoot” mode over a 180-degree
body-contouring orbit. The animal was allowed to return
to baseline heart rate and was then received an injection
of a 25 mCi bolus of 99mTc-sestamibi before obtaining a
rest SPECT, acquired in an analogous fashion.
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The rest and stress SPECT studies were processed in a
blinded fashion with the use of an integrated ADAC
Pegasys computer. Stress and rest circumferential count
profiles (polar plots) at the midventricular level were
constructed by dividing the midventricular short-axis im-
age into 60 angular segments centered on the ventricular
cavity, determining the number of counts per segment,
normalizing the number of counts in each segment to the
segment with the maximum number of counts (assigned a
reference value of 100), and plotting the normalized
counts per segment versus the angular position of the
segment. The polar plots were transferred to ASCII files
for further analysis with the program SIGMAPLOT (Jan-
del Scientific, Corte Madera, Calif.).
For each animal, the extent of myocardial ischemia
(“area”) was determined from the difference between the
rest and stress polar plots. The maximum severity of
ischemia (“ischemia maximum”) in the circumflex distri-
bution was determined by ascertaining the point of great-
est difference between the rest and stress plots and
measuring the difference in the plots at that point. The
percent improvement in myocardial perfusion for each
animal was calculated for these two parameters as (“pa-
rameter” at 3 weeks 2 “parameter” at 7 weeks 3 100)/
(“parameter” at 3 weeks).
Echocardiographic assessment of regional myocardial
function. Baseline regional myocardial function was as-
sessed by echocardiography at rest and during stress at the
time of vector administration. Animals were sedated and
placed in the left lateral decubitus position, and standard
two-dimensional and M-mode transthoracic images were
obtained with an HP2500 echocardiographic machine and
a 3.0/3.5 MHz dual-frequency transthoracic transducer
(Hewlett-Packard, Andover, Mass.). From the right
parasternal approach, short-axis, midpapillary views were
obtained at rest for 3 minutes. The animals then under-
went rapid left atrial pacing in a stepwise fashion to the
target ventricular rate of 200 beats/min, at which time
imaging was recorded for an additional 3 minutes.
Regional wall thickening was determined by a single
experienced investigator in a blinded fashion, tracing the
endocardial and epicardial surfaces of the left ventricle in
both diastole and systole using a Digisonics CardioRevue
System (Digisonics Inc., Houston, Tex.). Systolic wall
thickening in each of six equal radial 60-degree segments
was defined as mean systolic wall thickness 2 mean
diastolic wall thickness. Fractional wall thickening was
calculated as mean systolic wall thickening/mean diastolic
wall thickness. The ischemic and nonischemic zones for
each animal were defined from rapid atrial pacing images
at 3 weeks (baseline ischemia) as the two contiguous
segments with the lowest and highest fractional wall
thickening, respectively. This corresponded in all cases
with the circumflex region and the septum, respectively.
The same zones for each animal were analyzed in rapid
atrial pacing images at 7 weeks.
Ex vivo coronary angiography. When each animal was
put to death (4 weeks after vector administration), the
heart was arrested with 40 mEq of KCl and then perfu-
sion-fixed at 100 mm Hg with 1 L of McDowell-Trump
fixative (4% formaldehyde, 1% glutaraldehyde, 1%
NaH2PO4 and 0.3% NaOH adjusted to pH 7.2). Ex vivo
coronary angiography was performed by the same angiog-
rapher in a blinded fashion using a 5F end-hole wedge
balloon catheter (Arrow Inc., Reading, Pa.) placed in the
left main coronary artery. By means of cinefluoroscopy in
Fig. 1. Schema of the experimental design. Three weeks after Ameroid constrictor placement, animals
were administered either AdGVVEGF121.10 (n 5 7) or the control vector AdNull (n 5 8) at 10 sites (10
8
pfu/site) distributed throughout the left ventricular region between the circumflex and left anterior
descending coronary arteries, as indicated.
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the standard right anterior oblique projection with con-
tinuous image acquisition, 5 ml of contrast medium
(Hypaque-76, Nycomed Inc., New York, N.Y.) was in-
jected at a continuous rate until the entire left anterior
descending coronary artery and its branches were com-
pletely opacified.21 Collateral vessels from the left ante-
rior descending coronary artery, which reconstituted the
circumflex coronary artery or obtuse marginal branch of
the circumflex coronary artery, were quantified by three
blinded observers using the grading method of Rentrop
and associates22 as follows: 0 5 no filling of collateral
vessels; 1 5 filling of collateral branches of the circumflex
or obtuse marginal branch without visualization of the
epicardial segment; 2 and 3 5 partial or complete filling of
the epicardial segment of the circumflex or obtuse mar-
ginal artery via collateral vessels, respectively.
Histologic evaluation. After angiography, the left ven-
tricle of each heart was sectioned into three rings in the
short axis. Forty 5 mm histologic sections from each heart
were taken at equidistant intervals around the basal and
midventricular rings, processed through paraffin, and
stained with hematoxylin and eosin. Histologic evidence
of infarction and inflammation for each tissue section was
graded by a pathologist blinded to treatment on a scale of
0 to 4 as follows: 0 5 none; 1 5 one to three small areas
involved; 2 5 less than 10% section surface; 3 5 more
than 10% up to 50% section surface; and 4 5 more than
50% section surface.
Statistical analysis. Treatment was assigned in an al-
ternating consecutive fashion to a total enrollment of 15
animals that could be evaluated for efficacy, with myocar-
dial ischemia area defined as the primary outcome vari-
able. Statistical analysis was carried out by means of the
Mann-Whitney nonparametric test. All results are ex-
pressed as mean 6 standard error of the mean.
Results
Overall assessment. All of the 19 animals en-
tered into the study (AdGVVEGF121.10, n 5 9;
AdNull, n 5 10) survived until put to death 7 weeks
after placement of the Ameroid constrictor, without
clinical evidence of toxicity. At 3 weeks (i.e., before
therapy), four of the 19 pigs (AdGVVEGF121.10,
n 5 2; AdNull treated, n 5 2) had evidence of
myocardial infarction in the circumflex region, as
demonstrated by (1) a fixed defect (no difference
between rest and stress) in the circumflex zone of
the 99mTc-sestamibi SPECT images and (2) a
thinned, akinetic posterolateral region of the left
ventricle in short-axis views during echocardiogra-
phy at rest. Consistent with the 99mTc-sestamibi
SPECT and echocardiography suggesting myocar-
dial infarction 3 weeks after Ameroid constrictor
placement, the gross pathologic evaluation 4 weeks
later showed myocardial scarring and thinning of at
least 25% of the total ventricular mass. All four pigs
in this subgroup also had histologic evidence of large
transmural infarction. On the basis of these data,
these four animals were excluded from further
analysis. Thus the group of animals evaluated for
efficacy of therapy included seven AdGV-
VEGF121.10-treated animals and eight AdNull
(control) animals.
In vivo expression of the AdGVVEGF.10 vector
was confirmed by demonstrating local myocardial
VEGF expression after myocardial injection of 108
pfu of AdGVVEGF121.10 (n 5 3). Three days after
administration of the vector, myocardial levels were
0.75 6 0.25 ng/mg protein, compared with back-
Table I. Quantitative assessment of regional stress-induced myocardial ischemia by 99mTc-labeled sestamibi
SPECT imaging
Time of study








(n 5 7) p Value
3 wk (vector administered) 3570 6 640 3200 6 390 0.8 30.7 6 3.6 26.8 6 2.1 0.2
7 wk 750 6 220 2140 6 400 0.005 11.0 6 2.2 22.3 6 1.7 0.04
*Values are mean 6 standard error of the mean; regional stress-induced was quantified by determining the area of ischemia and ischemia maximum as
described in Fig. 2, A and the Methods section.
Table II. Stress-induced regional contractile
dysfunction assessed by two-dimensional
echocardiography
Time of study
Difference in fractional wall





(n 5 7) p Value
3 wk (vector administered) 16 6 4.2 17.2 6 4.4 0.9
7 wk 20.06 6 3.3 12.4 6 4.0 0.03
Values are mean 6 standard error of the mean; Short-axis images of
two-dimensional echocardiograms were divided into six radial segments,
and the fractional wall thickening (systolic wall thickening as a percentage
of diastolic wall thickness) of the ischemic zones was assessed as described
in the Methods section. The percent difference in fractional wall thickening
of the nonischemic zone minus the ischemic zone was calculated for
AdNull and AdGVVEGF121.10; zero difference in fractional wall thicken-
ing signifies equivalent function in the ischemic and nonischemic zones.
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ground expression in AdNull-treated animals (p 5
0.01).
AdGVVEGF121.10-mediated increase in myocar-
dial perfusion. Circumferential count profiles (po-
lar plots) of 99mTc-sestamibi SPECT data from the
midventricular level were used to quantify (1) the
extent and severity of ischemia (“area”) and (2) the
most severe ischemia (“ischemia maximum”) (Fig.
2, A). Circumferential plots of rest images obtained
at 3 weeks typically demonstrated minimal perfusion
defects, compared with plots of stress (pacing) im-
ages, which revealed decreased perfusion in the
posterolateral region, corresponding to the oc-
cluded circumflex coronary artery distribution (Fig.
2, B and D). The ischemic area and ischemia
maximum were characteristically unchanged from
baseline in AdNull animals assessed 4 weeks after
vector administration (Fig. 2, B and C). In contrast,
AdGVVEGF121.10 animals demonstrated improve-
ment in myocardial perfusion 4 weeks after vector
administration, as demonstrated by decreases in the
ischemic area and ischemic maximum compared
with baseline (Fig. 2, D and E). Corresponding
changes were noted at the apical, midventricular,
and basal levels.
The ischemic area was similar in both the AdGV-
VEGF121.10 and AdNull control animals at the
time of vector administration (Table I). In contrast,
the ischemic area was significantly reduced at 7
weeks in the AdGVVEGF121.10 animals compared
with the AdNull animals. The “percent improve-
ment” in the area of ischemia of each animal 4
weeks after vector administration, compared with
baseline, was approximately 2.4-fold greater in the
AdGVVEGF121.10 animals than in the AdNull an-
imals (75% 6 6% vs 32% 6 11%, respectively, p 5
0.01).
The ischemia maximum in the circumflex distri-
bution was also the same for the AdGVVEGF121.10
animals and AdNull control animals at 3 weeks
(Table I). In contrast, 4 weeks after vector adminis-
tration, the ischemia maximum was significantly
decreased in the AdGVVEGF121.10 animals than in
the AdNull control animals. Similarly, the “percent
improvement” in the ischemia maximum was 2.5-
fold greater in AdGVVEGF121.10 animals than in
the AdNull control animals (56% 6 8% vs 22% 6
6%, p 5 0.01).
AdGVVEGF121.10-mediated improvement in
myocardial function. Three weeks after Ameroid
constrictor placement, myocardial function in the
ischemic circumflex region compared with the non-
ischemic septum was similar in the AdGV-
VEGF121.10 group compared with AdNull controls
as assessed by fractional wall thickening during
rapid atrial pacing (Table II). In contrast, by 4 weeks
after vector administration, AdGVVEGF121.10-
treated animals demonstrated significantly greater
improvement in fractional wall thickening during
rapid atrial pacing than did AdNull control animals.
Strikingly, contractile function in the circumflex
segment of the AdGVVEGF121.10 group approxi-
mated that of the septal (control) segment, as
reflected by an ischemic minus nonischemic zone
difference of “zero” in this analysis.
Fig. 2. Quantitative assessment of regional stress-in-
duced myocardial ischemia with 99mTc-labeled sestamibi
SPECT imaging. A, Schema of method using circumfer-
ential count profiles. Short-axis 99mTc-sestamibi images at
the midventricular level were analyzed as described in the
Methods section. The extent and severity (area) of myo-
cardial ischemia was determined from the difference
between the rest and stress circumferential count profile
curves. The greatest severity of ischemia (ischemia maxi-
mum) in the circumflex distribution was determined as the
greatest difference between the rest and stress circumfer-
ential count profiles.
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Angiographic assessment of coronary vessels. Ex
vivo angiography performed 4 weeks after vector
administration confirmed complete occlusion of
the proximal circumflex coronary artery by the
Ameroid constrictor in all animals. AdNull-
treated animals characteristically demonstrated
only partial filling of the obtuse marginal and
circumflex coronary arteries (Fig. 3, A). In con-
trast, animals that received AdGVVEGF121.10
typically demonstrated nearly complete reconsti-
tution of both the obtuse marginal and circumflex
coronary circulations (Fig. 3, B and C).
The collateral grade for the obtuse marginal
and circumflex coronary arteries was significantly
greater in the AdGVVEGF121.10 animals than
in the AdNull animals (Table III). Finally, the
total number of angiographically visible collat-
eral vessels filling the circumflex and obtuse mar-
ginal arteries was significantly greater in the
AdGVVEGF121.10 animals than in the AdNull
animals (Table III).
Histologic assessment. The myocardium in 13 of
the 15 animals in the study was available for assess-
ment of inflammation (AdGVVEGF121.10, n 5 5;
Fig. 2. Cont’d. B, Representative circumferential count profiles of an AdNull-treated animal at 3 weeks
(at the time of vector administration) at rest (upper part of the panel) and stress (atrial pacing; at the lower
part of the panel), showing a perfusion defect in the posterolateral region. C, Same animal as in panel B,
but at 7 weeks. There is minimal decrease in area of ischemia and ischemia maximum compared with 3
weeks. D, Representative circumferential count profiles of an AdGVVEGF121-treated animal at 3 weeks
(at the time of vector administration) at rest and stress (atrial pacing), showing a perfusion defect in the
posterolateral region. E, Same animal as in panel D, but at 7 weeks; there is a marked decrease in both area
of ischemia and ischemia maximum compared with observations at 3 weeks.
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AdNull, n 5 8). Minimal inflammation was detected
in the myocardium of these animals evaluated 4
weeks after therapy, with no difference in the extent
of inflammation between the AdGVVEGF121.10
and AdNull groups (overall intensity score 0.3 6
0.06 vs 0.4 6 0.08, p 5 0.4).
Discussion
This study demonstrates that Ad-mediated trans-
fer of the cDNA of human VEGF isoform 121
directly into the myocardium of Yorkshire swine
with an occluded circumflex coronary artery results
in significant and physiologically relevant improve-
ment in regional myocardial perfusion and contrac-
tile function during stress-induced myocardial isch-
emia. Importantly, this improvement was associated
with increased myocardial collateral vessel develop-
ment, “biologically bypassing” the experimentally
occluded coronary artery segment.
VEGF as a mediator of therapeutic angiogenesis.
Considerable information is available suggesting
that the VEGF protein can induce angiogenesis in a
variety of animal models of ischemia.5-9, 15 In regard
to cardiac ischemia, a single intracoronary bolus of
VEGF165 improves blood flow to the ischemic re-
gion,9 and continuous infusion of the VEGF165
protein via indwelling catheters increases collateral
blood flow to ischemic myocardium and the numeric
density of intramyocardial distribution vessels.5 Fi-
nally, continuous administration of VEGF165 to the
surface of the myocardium over 6 weeks reduces the
ischemic zone and improves ejection fraction and
regional myocardial wall thickening as assessed by
magnetic resonance imaging.8
Our choice of VEGF for this study is based on
these findings and the endothelial cell specificity
of VEGF, which offers potential advantages over
the use of other growth factors with angiogenic
properties (such as the fibroblast growth factors),
which are also mitogenic for cells such as fibro-
blasts and smooth muscle cells, and thus theoret-
ically impose the risk of unwanted fibrosis or
Fig. 3. Representative ex vivo angiograms of pig hearts 7
weeks after placement of Ameroid constrictors. The vec-
tors were administered 3 weeks after placement of the
Ameroid constrictor. A, AdNull. B and C, AdGV-
VEGF121.10 (referred to as AdVEGF121). The Ameroid
constrictor completely occludes the circumflex artery in
both the AdNull and AdVEGF121-treated animals. The
AdNull-treated animal demonstrates only minimal filling
of the distal circumflex artery. In contrast, the Ad-
VEGF121-treated animals show nearly complete recon-
stitution of the circumflex artery.
Table III. Quantitative assessment of collateral





(n 5 7) p Value
Collateral grade (scale: 0-3)
To obtuse marginal 2.9 6 0.1 1.8 6 0.2 0.03
To circumflex 2.8 6 0.1 1.9 6 0.3 0.04
Collateral vessel number† 4.0 6 0.4 2.0 6 0.3 0.001
*Values are mean 6 standard error of the mean determinations of three
blinded observers as described in the Methods section.
†Number of angiography-visible collateral vessels observed between the
left anterior descending and the circumflex or obtuse marginal arteries.
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smooth muscle cell hyperplasia.3, 23, 24 Although
the major VEGF isoforms appear to be equipo-
tent in angiogenic potential, our choice of the
cDNA coding for the 121 amino acid isoform of
VEGF was based on the knowledge that the
VEGF121 isoform does not bind heparin and thus
may diffuse throughout the myocardium more
readily than the other isoforms.11, 12
Ad-mediated gene transfer as a strategy for
VEGF-related therapeutic angiogenesis. Gene
therapy holds several potential advantages over a
protein-based strategy for therapeutic angiogenesis.
Gene transfer provides the equivalent of a “slow-
release depot,” providing high concentrations of the
therapeutic protein for a relatively extended period.
Ad vector expressing VEGF provides myocardial
expression of VEGF protein for up to 7 days.17 In
contrast, the VEGF protein has a very short biologic
half-life in the circulation,6 and most previous stud-
ies have consequently required continuous infusions
or repetitive dosing of the growth factor to achieve
a therapeutic effect.5, 8, 15 Another potential advan-
tage of gene therapy over protein-mediated angio-
genic therapy is that gene transfer can be strategized
to provide delivery of a high concentration of VEGF
localized to the ischemic sites. In contrast, systemic
administration of a single large bolus of VEGF
protein can cause hypotension, and systemic therapy
carries the theoretic risk of inducing inappropriate
angiogenesis at sites of vascular derangement, or at
sites where angiogenesis might have major adverse
consequences, such as the retina, the synovium, and
in occult tumors.3, 9, 11, 12, 16
Although three gene transfer systems—naked
plasmids, herpes simplex virus, and Ad— have
been used to induce angiogenesis with VEGF in
experimental models, we have focused on Ad
vectors because their inherent properties make
them ideal for use in therapeutic angiogenesis. Ad
vectors achieve gene transfer in both dividing and
nondividing cells, with high levels of protein ex-
pression in cardiovascular relevant sites, such as
myocardium, vascular endothelium, and skeletal
muscle.14, 17, 25, 26 The new gene transferred by an
Ad vector functions in an epi-chromosomal posi-
tion and thus carries little risk of inappropriately
inserting the newly transferred gene in a critical
site of the genome.27 Most important, whereas
long-term expression of angiogenic proteins might
induce excessive, disorganized blood vessel for-
mation, Ad vectors are highly efficient at achiev-
ing high levels of gene expression in cardiovascu-
lar tissues for only 1 to 2 weeks, thus limiting
expression to that necessary to induce angiogen-
esis.14, 17, 18 Consistent with the concept that Ad
vectors can be used to deliver genes relevant to
inducing myocardial angiogenesis, an Ad vector
has been used to deliver the fibroblast growth
factor–5 cDNA to the ischemic porcine myocar-
dium, with resulting increases in perfusion, func-
tion, and histologic evidence of angiogenesis.14
Host immune response is a potential disadvantage
to the use of Ad vectors in some gene transfer
applications. With the use of clinical grade vectors,
as in the present study, however, inflammation does
not appear to be a significant problem. The cellular
immune response that likely limits vector expression
is actually an advantage for the application of ther-
apeutic angiogenesis, as previously discussed. Fi-
nally, although it is unlikely that repeated adminis-
trations will be needed, the theoretic development
of neutralizing antibodies directed against the Ad
vector that might limit the effectiveness of repeated
vector administrations can likely be overcome by the
use of Ad vectors of different serotypes or by
immunosuppressive therapy.28
Ad-mediated angiogenesis as a biologic revascu-
larization strategy. The primary significance of the
present results is that a one-time direct myocardial
administration of an Ad vector containing the
VEGF121 cDNA induces the development of collat-
eral vessels adequate to enhance myocardial perfu-
sion and ameliorate regional myocardial contractile
dysfunction in the setting of stress-induced myocar-
dial ischemia. The observation in control animals of
some collateral vessel development is consistent
with evidence of the limited, incomplete nature of
the endogenous processes of angiogenesis and col-
lateralization that are known to occur in the setting
of ischemia. In this context, the therapeutic angio-
genesis described in this study can be considered as
a logical enhancement of the normal, endogenous
response to ischemia. With the evidence that Ad
vectors are capable of delivering new genetic infor-
mation safely to human beings in vivo,27 the clinical
applications of this strategy include its use as a novel
therapeutic “biologic bypass” in patients with coro-
nary disease.
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Discussion
Dr. Andrew S. Wechsler (Richmond, Va.). This work
demonstrates the efficacy of Ad-based gene transfer as a
means to achieve a potentially clinically applicable treat-
ment strategy. It far transcends studies that have focused
solely on demonstrating the ability to transfer genetic
material to the myocardium. Locally enhanced expression
of VEGF in the vicinity of ischemic myocardium improved
collateral vessel density, regional blood flow, and myocar-
dial function under stress conditions. The induction of
new vessel growth by VEGF or its genetic progenitors is
so promising that the Food and Drug Administration has
recently approved a clinical trial proposed by Isner and his
colleagues at the New England Medical Center. In their
study, naked DNA coding for VEGF is to be infused into
ischemic extremities unsuitable for surgical revasculariza-
tion.
I have several questions for the authors:
Why did you select the 121 VEGF?
You noted minimal inflammation. Other investigators
have consistently observed worrisome degrees of inflam-
mation associated with Ad gene transfer. Why do you
think inflammation was so minimal?
Why did you choose an Ad vector over naked DNA or
plasmid-based gene transfer?
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Have you performed experiments to determine the
duration of gene expression or demonstrated VEGF
within the myocardium?
Do you believe you have accelerated time-dependent
collateral development or that you have induced a quali-
tative generation of neocollaterals?
Finally, do you think intravascular administration via
the left anterior descending coronary artery would have
had a comparable effect, inasmuch as this would allow a
more convenient use of this technique if it were to become
clinically applicable?
Dr. Mack. We chose the 121 isoform as opposed to the
other isoforms because the 121 isoform is known to bind
to just one of the VEGF receptors, unlike the other
isoforms. Certain inflammatory cells such as monocytes
and some carcinoma cell lines are known to express both
or one of the VEGF receptors. We thought that the
VEGF121 isoform would provide us with the most speci-
ficity for endothelial cells in that it binds to the Flk-1
receptor and not to the Flt-1 receptor.
In addition, VEGF121 does not have as much affinity for
heparin as does VEGF165 and would diffuse more into the
ischemic milieu and therefore potentially enhance any
therapeutic effect.
Concerning inflammation, contamination by replica-
tion-competent viral particles to a large extent determines
the degree of inflammation when Ad vectors are used.
The vector that we used was free of replication-competent
particles up to 108 pfu. As Ad vector technology advances,
the degree of inflammation potentially can become less
and less.
Disadvantages of the Ad vector for many of the inher-
ited diseases, in that it expresses the transgene for only a
limited duration, is one of the main reasons why we chose
an Ad for this application. It was our hypothesis that a
localized, yet transient degree of expression would be just
enough to induce a neovascular response. Any prolonged
degree of expression raises the concern of disorganized
angiogenesis, inappropriate angiogenesis at other sites,
such as the retina, occult tumors, and arthritic joints. The
fact that the first-generation Ad vectors are known to
express the transgene only transiently is a true advantage
for this application,.
Regarding the duration of expression, in this porcine
model we have done only very preliminary studies looking
at gene expression and quantifying gene expression. Prior
work in our laboratory done by Christopher Magovern has
demonstrated that an Ad vector expressing VEGF165,
expression can be as long as 7 to 14 days. Although we
have not studied the duration of expression to date in the
porcine model, we are planning to do that study and
validate the fact that expression is transient.
Dr. Wechsler inquired about the mechanism contribut-
ing to our results, whether it is an increase in the
endogenous response or a new generation of blood ves-
sels. It is probably a combination of several things. The
endogenous response probably is enhanced to some de-
gree; however, other investigators, using VEGF and other
growth factors and certain mitotic assays like bromode-
oxyuridine and proliferating cell nuclear antigen, have
demonstrated that a new generation of blood vessels
develops. Therefore the collateral vessel response contrib-
uting to improved blood flow is likely a multifactorial
process.
As far as the route of administration through the left
anterior descending coronary artery, it was our purpose to
directly inject the vector into the myocardium to avoid any
systemic toxicity. Catheter-related devices that allow in-
jection into the coronary vessel raise the concern of a
systemic administration.
Dr. Margaret D. Allen (Seattle, Wash.). Did antibodies
to Ad develop?
Dr. Mack. We looked at neutralizing antibodies at the
time of Ameroid constrictor placement, the time of vector
administration, and when the animals were put to death.
Neutralizing antibodies to the Ad were observed at the
time of sacrifice at a very low level. This has to be taken in
context with what has been published for the most part in
small animals, where the same dose of vector is given in an
animal that is perhaps a thousand times smaller. The
degree of neutralization in these experiments was rela-
tively minimal.
Dr. Allen. That would be interesting, because it might
affect retreatment in the future, for instance, for an
ischemic patient who might need more than one treat-
ment. It would be interesting to know whether the in-
tramyocardial injection perhaps is less likely to induce an
antibody response than an intravenous injection.
Dr. Mack. That is a very insightful point. Perhaps the
route of administration does play a role here. As far as
being able to administer the vector twice, there are 49
different Ad serotypes, and studies have been published
whereby just altering the serotype can circumvent neutral-
izing immunity. This does not escape the cytotoxic T-cell
response that clears the virus. However, clearly a repeat
administration using an alternate serotype or immuno-
modulation can be achieved.
Mr. Reida M. El Oakley (London, England). I agree
with Dr. Wechsler that your data would be more informa-
tive if you included two more control groups, one with the
plasmid only and one with saline solution or nothing
altogether.
Dr. Mack. We actually have in progress a treatment
group in which the animals receive no injection at the
second operation. Preliminarily, there appears to be no
difference between that group and our AdNull-treated
controls.
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